NEO लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 120342 min ago

@ $14.92

जारी किया गया: 15 Feb 2024 @ 02:25

वापसी: 4.36%

पिछला सिग्नल: Feb 15 - 00:41

पिछला सिग्नल: खरीदें

वापसी: 1.53 %

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 01:30):

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments...

Stats
आज की मात्रा	547 291
औसत मात्रा	955 000
बाजार मूल्य	1.99B
EPS	$0 ( 2024-04-30 )
अगली कमाई की तारीख	( $-0.0300 ) 2024-05-13
Last Dividend	$0.400 ( 2020-12-17 )
Next Dividend	$0 ( N/A )
P/E	-23.59
ATR14	$0.0120 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-02	Stone Warren	Buy	29 976	Stock Option (Right to Buy)
2024-05-02	Stone Warren	Buy	17 908	Restricted Stock Unit
2024-05-02	Stone Warren	Buy	17 908	Performance Stock Unit
2024-05-01	Olivo Alicia C	Sell	652	Common Stock
2024-05-02	Harris Melody	Buy	19 984	Stock Option (Right to Buy)

INSIDER POWER
94.65
Last 90 transactions
Buy: 3 508 134 \| Sell: 93 304

मात्रा सहसंबंध

लंबा: 0.48 (neutral)

छोटा: 0.76 (moderate)

Signal:(57.425) Neutral

Neogenomics Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
GNUS	0.908
CNEY	0.897
LMDX	0.886
BROG	0.871
UCL	0.869
CVAC	0.869
CRGE	0.868
LGVN	0.868
BXRX	0.866
PCSA	0.862

10 सबसे अधिक नकारात्मक सहसंबंध
PTMN	-0.895
IMPP	-0.869
APEN	-0.865
IMRA	-0.86
EYEG	-0.859
FRG	-0.85
XOMAO	-0.849
AGFS	-0.838
NESR	-0.832
RNLC	-0.829

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Neogenomics Inc सहसंबंध - मुद्रा/वस्त्र

0.48
( neutral )

0.72
( moderate )

0.00
( neutral )

0.24
( neutral )

0.52
( weak )

-0.72
( moderate negative )

Neogenomics Inc वित्तीय

Annual	2023
राजस्व:	$591.64M
सकल लाभ:	$244.60M (41.34 %)
EPS:	$-0.700

FY	2023
राजस्व:	$591.64M
सकल लाभ:	$244.60M (41.34 %)
EPS:	$-0.700

FY	2022
राजस्व:	$509.73M
सकल लाभ:	$187.90M (36.86 %)
EPS:	$-1.160

FY	2021
राजस्व:	$484.33M
सकल लाभ:	$187.06M (38.62 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

Neogenomics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Neogenomics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 3.97 - low (31.86%) | Divividend Growth Potential Score: 0.0751 - No dividend growth expected in the near future

Information

First Dividend	$0.400	2020-12-17
Last Dividend	$0.400	2020-12-17
Next Dividend	$0	N/A
Payout Date	2020-12-30
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.400	--
Avg. Dividend % Per Year	0.09%	--
Score	0.65	--
Div. Sustainability Score	3.97
Div.Growth Potential Score	0.0751
Div. Directional Score	2.02	--

Next Divdend (Est)
(2024-05-08)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.65

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2020	$0.400	1.38%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.138	1.500	-2.76	-4.14	[0 - 0.5]
returnOnAssetsTTM	-0.0514	1.200	-1.712	-2.05	[0 - 0.3]
returnOnEquityTTM	-0.0894	1.500	-2.10	-3.16	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	7.48	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.87	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	4.33	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.331	-1.500	4.48	-6.72	[0 - 0.6]
interestCoverageTTM	50.47	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.120	2.00	-0.0401	-0.0802	[0 - 30]
freeCashFlowPerShareTTM	-0.314	2.00	-0.157	-0.314	[0 - 20]
debtEquityRatioTTM	0.588	-1.500	7.65	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.412	1.000	6.46	6.46	[0.2 - 0.8]
operatingProfitMarginTTM	-0.165	1.000	-5.30	-5.30	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.0279	1.000	-1.266	-1.266	[0.2 - 2]
assetTurnoverTTM	0.372	0.800	-0.851	-0.681	[0.5 - 2]
Total Score				3.97

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-23.31	1.000	-2.46	0	[1 - 100]
returnOnEquityTTM	-0.0894	2.50	-1.353	-3.16	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.314	2.00	-0.105	-0.314	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.120	2.00	-0.0401	-0.0802	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.67	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0249	1.000	-3.12	0	[0.1 - 0.5]
Total Score				0.0751

Neogenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

के लिए वास्तविक समय के अद्यतन Neogenomics Inc [NEO]

Upcoming Earnings Alert

Neogenomics Inc Dividend Information - No Dividend Player

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)